Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context

Antonio González-Martín, Ursula A Matulonis, Jacob Korach, Mansoor R Mirza, Kathleen N Moore, Xiaohua Wu, Whitney York, Divya Gupta, Stanislav Lechpammer, Bradley J Monk*

*Corresponding author af dette arbejde

Abstract

We reviewed clinical data for niraparib monotherapy in BRCA-mutated (BRCAm) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as first-line maintenance therapy and by 73-78% in recurrent disease. In heavily pretreated OC, efficacy was greater in the BRCAm versus non-BRCAm cohort. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety and QoL evidence demonstrate niraparib maintenance monotherapy has a positive benefit:risk ratio in BRCAm OC. Niraparib significantly improved progression-free survival as first-line maintenance therapy in all patients with OC (i.e., of any biomarker status).

OriginalsprogEngelsk
TidsskriftFuture oncology (London, England)
Vol/bind18
Udgave nummer23
Sider (fra-til)2505-2536
Antal sider32
ISSN1479-6694
DOI
StatusUdgivet - jul. 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context'. Sammen danner de et unikt fingeraftryk.

Citationsformater